NEEDLES INCLUDED

Retatrutide – A New Generation of Therapy for Obesity and Metabolic Diseases

Retatrutide (LY3437943) is an innovative peptide developed by Eli Lilly, currently in advanced clinical trials as a potential treatment for obesity, type 2 diabetes, and metabolic syndrome. This substance is considered one of the most promising future therapies for metabolic disorders.

What is Retatrutide?

Retatrutide is a triple agonist at the GLP-1, GIP, and glucagon receptors, making it the first drug of its kind in the world. This means it simultaneously targets three key metabolic regulatory mechanisms:

• GLP-1 – reduces appetite, slows gastric emptying, and improves blood sugar control
• GIP – increases insulin secretion and improves tissue sensitivity to insulin
• Glucagon – stimulates fat burning and increases the body’s energy consumption

This allows Retatrutide not only to reduce calorie intake but also activates fat-burning mechanisms, distinguishing it from other GLP-1 therapies.

Clinical Studies and Potential Benefits

In clinical studies, Retatrutide demonstrated:

• significant weight loss (in some patients exceeding 20–25%)
• reduction in visceral and liver fat
• improvement in insulin sensitivity
• reduction in blood glucose levels
• improvement in lipid profile

These results mean that Retatrutide is often compared to Tirzepatide, but with an additional fat-burning mechanism.

Retatrutide Benefits

• Triple metabolic action (GLP-1, GIP, glucagon)
• Potent weight loss
• Reduced appetite and appetite control
• Activation of fat burning
• Improved glycemic control
• Improved lipid profile
• Potential use in the treatment of obesity, diabetes, and fatty liver disease

Retatrutide Dosage

In clinical trials, Retatrutide is administered by subcutaneous injection, usually once a week. The dosage is gradually increased to minimize side effects and adjust for patient tolerance.

Final dosing regimens will be established after the studies are completed and the drug is approved by regulatory authorities.

Side Effects

Like other GLP-1 medications, Retatrutide may cause gastrointestinal side effects, such as:

• nausea
• vomiting
• diarrhea or constipation
• a feeling of fullness
• epigastric discomfort
• decreased appetite

These symptoms typically occur at the beginning of therapy and decrease with continued use.